Skip to main content

Table 3 The outcomes of RR, 95% CI, and I2 in CR, PR, ORR, DCR, 1-year survival rate, and 2-year survival rate

From: Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis

Analysis

Number Of Concerning Trials

Pooled RR

95%CI

P-Value

I2 For Homogeneity

CR

7

1.49

0.95–2.33

0.08

27%

PR

6

1.08

0.88–1.32

0.47

68%

ORR

8

1.08

1.00–1.16

0.05

36%

DCR

7

1.02

0.96–1.08

0.49

0%

1-Year Survival Rate

4

1.11

0.96–1.28

0.18

0%

2-Year Survival Rate

3

1.77

1.19–2.63

0.005

42%

  1. DCR disease control rate